{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:46:32Z","timestamp":1792406792470,"version":"4.4.0"},"reference-count":38,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD occurs in approximately 20%\u201325% of cases of adult AML and is associated with increased relapse risk and shorter survival.\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD status informs AML risk at diagnosis, but its dynamic changes during disease evolution are not well defined. We hypothesized that divergent\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD clonal trajectories are shaped by preexisting molecular features detectable at diagnosis. We analyzed 319 intensively treated adults who were newly diagnosed with non\u2010M3\n                      <jats:italic>de novo<\/jats:italic>\n                      AML who experienced relapse and had paired\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD mutation data at diagnosis and relapse. Patients were classified into four clonal evolution patterns: maintained\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD negative (\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD\n                      <jats:sup>negative<\/jats:sup>\n                      ),\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD loss (\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD\n                      <jats:sup>lost<\/jats:sup>\n                      ),\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD acquisition (\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD\n                      <jats:sup>acquired<\/jats:sup>\n                      ), and maintained\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD positive (\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD\n                      <jats:sup>positive<\/jats:sup>\n                      ). The\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD\n                      <jats:sup>positive<\/jats:sup>\n                      group was strongly associated with concurrent\n                      <jats:italic>NPM1<\/jats:italic>\n                      and\/or\n                      <jats:italic>DNMT3A<\/jats:italic>\n                      mutations, which were enriched compared with those in other groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001). ELN 2022 risk categories differed across clonal evolution patterns, with favorable\u2010risk disease declining\u00a0progressively from the\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD\n                      <jats:sup>negative<\/jats:sup>\n                      to the\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD\n                      <jats:sup>positive<\/jats:sup>\n                      group (44.3%\u20136.1%) while intermediate\u2010risk disease rose correspondingly (21.2%\u201373.5%; both\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001). With a median follow\u2010up of 96.8\u00a0months, patients in the\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD\n                      <jats:sup>acquired<\/jats:sup>\n                      or\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD\n                      <jats:sup>positive<\/jats:sup>\n                      group had significantly inferior relapse\u2010free and overall survival compared with those in the\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD\n                      <jats:sup>negative<\/jats:sup>\n                      group (\n                      <jats:italic>p\u00a0=<\/jats:italic>\n                      \u00a00.009 and\n                      <jats:italic>p\u00a0=<\/jats:italic>\n                      \u00a00.018, respectively, in univariate analyses;\n                      <jats:italic>p\u00a0=<\/jats:italic>\n                      \u00a00.001 and\n                      <jats:italic>p\u00a0=<\/jats:italic>\n                      \u00a00.006, respectively, in multivariate analyses adjusted for individual genetic risk features). Transcriptomics showed enrichment of inflammatory pathways in\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD\n                      <jats:sup>positive<\/jats:sup>\n                      cases that persisted after adjustment for\n                      <jats:italic>NPM1<\/jats:italic>\n                      \/\n                      <jats:italic>DNMT3A<\/jats:italic>\n                      co\u2010mutations and\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD allelic ratio, together with an inferred monocyte\u2010rich profile. Overall,\n                      <jats:italic>FLT3<\/jats:italic>\n                      \u2010ITD evolution is associated with distinct genomic and transcriptomic features present at diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>202203013RSD<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hon.70261","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:16:06Z","timestamp":1790075766000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Divergent Clonal Trajectories of\n                    <i>FLT3<\/i>\n                    \u2010ITD in Acute Myeloid Leukemia and Their Clinical and Transcriptomic Associations"],"prefix":"10.1002","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4174-8766","authenticated-orcid":false,"given":"Xavier Cheng\u2010Hong","family":"Tsai","sequence":"first","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Taiwan University Hospital  Taipei Taiwan"},{"name":"Department of Hematology Oncology National Taiwan University Cancer Center, National Taiwan University Hospital  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4571-3328","authenticated-orcid":false,"given":"Yu\u2010Sung","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Taiwan University Hospital  Taipei Taiwan"},{"name":"Graduate Institute of Clinical Medicine College of Medicine National Taiwan University  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4513-2472","authenticated-orcid":false,"given":"Feng\u2010Ming","family":"Tien","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Taiwan University Hospital  Taipei Taiwan"},{"name":"Department of Hematology Oncology National Taiwan University Cancer Center, National Taiwan University Hospital  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8208-353X","authenticated-orcid":false,"given":"Min\u2010Yen","family":"Lo","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Taiwan University Hospital Yunlin Branch  Yunlin Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6090-9000","authenticated-orcid":false,"given":"Yuan\u2010Yeh","family":"Kuo","sequence":"additional","affiliation":[{"name":"Tai\u2010Chen Cell Therapy Center National Taiwan University  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8425-619X","authenticated-orcid":false,"given":"Mei\u2010Hsuan","family":"Tseng","sequence":"additional","affiliation":[{"name":"Tai\u2010Chen Cell Therapy Center National Taiwan University  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen\u2010Ling","family":"Peng","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Taiwan University Hospital  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5052-9445","authenticated-orcid":false,"given":"Chi\u2010Yuan","family":"Yao","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Taiwan University Hospital Yunlin Branch  Yunlin Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6721-8055","authenticated-orcid":false,"given":"Szu\u2010Chi","family":"Yao","sequence":"additional","affiliation":[{"name":"Division of Hematological Oncology Department of Internal Medicine Chi\u2010Mei Medical Center  Tainan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7160-2285","authenticated-orcid":false,"given":"Chien\u2010Chin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine National Taiwan University Hospital  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7965-7579","authenticated-orcid":false,"given":"Bor\u2010Sheng","family":"Ko","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Taiwan University Hospital  Taipei Taiwan"},{"name":"Department of Hematology Oncology National Taiwan University Cancer Center, National Taiwan University Hospital  Taipei Taiwan"},{"name":"Tai\u2010Chen Cell Therapy Center National Taiwan University  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yao","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Taiwan University Hospital  Taipei Taiwan"},{"name":"Department of Hematology Oncology National Taiwan University Cancer Center, National Taiwan University Hospital  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-5593","authenticated-orcid":false,"given":"Hwei\u2010Fang","family":"Tien","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Taiwan University Hospital  Taipei Taiwan"},{"name":"Department of Internal Medicine Far\u2010Eastern Memorial Hospital  New Taipei City Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin\u2010An","family":"Hou","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Taiwan University Hospital  Taipei Taiwan"},{"name":"Graduate Institute of Clinical Medicine College of Medicine National Taiwan University  Taipei Taiwan"},{"name":"Division of General Medicine Department of Internal Medicine National Taiwan University Hospital  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2967-698X","authenticated-orcid":false,"given":"Wen\u2010Chien","family":"Chou","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Taiwan University Hospital  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1406184"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.65"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1516192"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010018\u20100357\u20109"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26892"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010021\u201001454\u2010z"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1614359"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(23)00464\u20106"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01911"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007626"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.cd\u201018\u20101453"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.5858\/2009\u20100292\u2010oa.1"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022697"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003398"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014672"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010022\u201001613\u20101"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003738"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010022\u201000774\u20107"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010017\u20100022\u2010y"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq402"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010019\u20100483\u2010z"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587\u2010019\u20100114\u20102"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13038"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010018\u20100034\u2010z"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201001\u2010693879"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1106968"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010020\u201019119\u20108"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.7554\/elife.93019"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.2991\/chi.d.190310.001"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102007\u201010\u2010119230"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003701"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010024\u201045916\u20106"},{"issue":"6","key":"e_1_2_9_36_1","first-page":"2140","article-title":"Overexpression and Constitutive Activation of FLT3 Induces STAT5 Activation in Primary Acute Myeloid Leukemia Blast Cells","volume":"9","author":"Spiekermann K.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101137"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.811144"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004226"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70261","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.70261","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:14:18Z","timestamp":1792404858000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/hon.70261"],"URL":"https:\/\/doi.org\/10.1002\/hon.70261","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-04-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70261"}}